Journal
RHEUMATOLOGY
Volume 53, Issue 11, Pages 1927-1939Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keu170
Keywords
autoinflammatory; periodic fevers; familial Mediterranean fever; genetic; biologic agents
Categories
Funding
- Novartis
- Rosetrees Trust [M8-F1-CD1] Funding Source: researchfish
Ask authors/readers for more resources
During the past 15 years, a growing number of monogenic inflammatory diseases have been described and their respective responsible genes identified. The proteins encoded by these genes are involved in the regulatory pathways of inflammation and are mostly expressed in cells of the innate immune system. Diagnosis remains clinical, with genetic confirmation where feasible. Although a group of patients exhibit episodic systemic inflammation (periodic fevers), these disorders are mediated by continuous overproduction and release of pro-inflammatory mediators, such as IL-1 and IL-6, and TNF and are best considered as autoinflammatory diseases rather than periodic fevers. Treatment with biologic agents that block these cytokines, particularly IL-1, has proved to be dramatically effective in some patients. Still, in many cases of autoinflammation no genetic abnormalities are detected and treatment remains suboptimal, raising the question of novel pathogenic mutations in unexplored genes and pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available